Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Endometrial Cancer
Would you consider the addition of trabectedin to adjuvant doxorubicin in a patient with IVB leiomyosarcoma with completely resected disease (hysterectomy and thigh mass with negative margins)?
Related Questions
Would you treat with extended field pelvic radiation for a patient with FIGO IIIC1 endometrial cancer who was found with isolated tumor cells (ITCs) on a single paraaortic sentinel lymph node?
If you recommend chemotherapy for early-stage uterine serous carcinoma, do you prefer 3 or 6 cycles?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
What adjuvant treatment would you recommend for a patient with FIGO 2023 IIIB2 endometrioid endometrial adenocarcinoma (Grade 3, p53mut, MMR proficient), metastatic to the uterine serosa, bilateral ovaries, and anterior peritoneal reflection?
Do you perform routine pelvic exams on patients undergoing active treatment for gynecologic cancer without GYN symptoms?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
Following surgical staging, what adjuvant therapy would you recommend for stage IB grade 3 endometrioid endometrial carcinoma with +LVSI?
How would you sequence adjuvant chemo-immunotherapy (paclitaxel/carbo/pembro or paclitaxel/carbo/dostarlimab) with EBRT and vaginal cuff brachytherapy in advanced uterine cancer that meets clinical criteria for both EBRT and chemo-IO?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?
Would you consider trying Pembrolizumab + Lenvatinib after progression on first-line Carboplatin + Paclitaxel + Immunotherapy for metastatic endometrial cancer?
